Navigating Systemic Therapy in Advanced Thyroid Carcinoma: From Standard of Care to Personalized Therapy and Beyond.

J Endocr Soc · 2018 · PMC6141902 · PMID 30250937

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients harboring RAS mutations showed a trend toward improved OS (HR, 0.37; 95% CI, 0.10 to 1.42) and PFS (HR, 0.15; 95% CI, 0.02 to 1.10).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.